Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
2 way Dual Activation GHRH-R (CJC-1295) + GHS-R1a (Ipamorelin) two complementary pituitary targets 2-4x GH AUC Demonstrated Synergy Area under the GH curve 2 to 4 times greater than each peptide in monotherapy 5.8 - 8.1 days CJC-1295 Half-Life Sustained elevation of IGF-1 for 9 to 11 days after a single injection 10 mg Pre-formulated mix 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin per vial | Purity 99% HPLC Selective Hormonal Profile Ipamorelin: no increase in cortisol, prolactin or ACTH (Raun et al., 1998) Mechanism of Action Dual-Channel Synergy Simultaneous activation of GHRH-R and GHS-R1a for amplified GH stimulation GHRH Lane CJC-1295 GHRH Analog (Mod GRF 1-29) A synthetic peptide of 29 amino acids that selectively binds to the GHRH receptor on pituitary somatotroph cells
Supplements: Inositol, chromium, and omega-3s can support metabolic and reproductive health
Unlike traditional GLP-1 receptor agonists, tirzepatide is more selective for the GIP receptor, resulting in a more balanced activation of these receptors
How is KPV administered
Ask our experts
US$ 26.87
US$ 28.75
US$ 29.36
US$ 23.12
